ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 2 of 44
УЖМБС 2022, 7(3): 14–20
Medicine. Reviews

Nonspecific Reactive Hepatitis – Unknown or Forgotten Diagnosis? (Short Review and Invitation to Discussion)

Boichak M. P. 1, Fedorova O. O. 1, Illyashenko Yu. M. 2, Zhurko M. M. 1, Antonov A. B. 2

The purpose of the study was to analyze and summarize information from the sources of scientific literature on nonspecific reactive hepatitis. Materials and methods. Analytical and bibliosemantic methods were used in the study. The search was performed in Google Scholar, NCBI, PUBMED and Web of Science databases using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) recommendations. Results and discussion. Acute and chronic liver diseases rank as one of the leading places in the structure of pathology of internal organs. The consequence of these diseases in many cases is the development of cirrhosis of the liver, which ranks 11th among the leading causes of death and 15th among the causes of morbidity in the world. Among hepatopathies, nonspecific reactive hepatitis (code K75.2 for ICD-10; DB97 for ICD-11) is rarely mentioned and diagnosed – secondary hepatitis caused by several endogenous and exogenous factors that reflect the liver's response to any somatic disease. There are few publications on this problem, but there are many publications on the deviation of liver function tests: bilirubin, alanine and aspartate aminotransferase, alkaline phosphatase, gamma-glutamyltranspeptidase in many pathological conditions, including in critically ill patients regardless of their trauma, cardiac and acute surgical pathology, intestinal disorders. Frequent signs of hepatic dysfunction in many diseases, along with a small number of clinical diagnoses of nonspecific reactive hepatitis, indicate a problem of underdiagnosis, which can be explained by the lack of clear clinical, laboratory and instrumental signs of this disease. Determination of biomarkers of the liver function used in routine clinical practice requires qualitative and quantitative clarification, ultrasound is not always informative, and computed tomography is not always available. This indicates the urgency of the problem of defining the concept and criteria for the diagnosis of nonspecific reactive hepatitis and the need for large-scale clinical studies, especially in critical conditions of various etiologies, in the pathogenesis of which are hemodynamic disorders and systemic inflammatory response. Conclusion. The low diagnosis of nonspecific reactive hepatitis can be explained not only by the ignorance of doctors, but also by the lack of clear diagnostic criteria. The true prevalence of nonspecific reactive hepatitis does not correspond to the frequency of pathology in clinical diagnoses

Keywords: liver, nonspecific reactive hepatitis, hepatic dysfunction, risk factors

Full text: PDF (Ukr) 267K

  1. Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis (Hoboken). 2021 Jun 4;17(5):365-370. PMID: 34136143. PMCID: PMC8177826.
  2. Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020 Nov;18(12):2650-2666. PMID: 31401364. PMCID: PMC7007353.
  3. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266.
  4. WHO. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) Version for 2010. Available from:
  5. WHO. ICD-11 for Mortality and Morbidity Statistics (Version : 02/2022). Available from:
  6. Popper H, Schaffner F. Liver: structure and function. NY-Toronto-London: McGraw-Hill Book Company Inc.; 1957. 777 p.
  7. Gubergryts NB, Lukashevych GM. Kryptogennyy gepatyt: zagadochnyy i mnogolykyy [Cryptogenic hepatitis: mysterious and many-sided]. Zdorov'ya Ukrayiny. 2013;9:14-17. [Russian]
  8. Nurmagomaev MS, Magomedova ZS, Kagramanova ZS. Lyteraturnyy obzor: khronycheskye gepatyty v klynyke vnutrennykh bolezney [Literature review: chronic hepatitis in the clinic of internal diseases]. Nauchnoe obozrenye. Medytsynskye nauky. 2016;5:77-91. [Russian]
  9. Thomson SJ, Cowan ML, Johnston I, Musa S, Grounds M, Rahman TM. 'Liver function tests' on the intensive care unit: a prospective, observational study. Intensive Care Med. 2009 Aug;35(8):1406-11. PMID: 19513695.
  10. Horvatits T, Drolz A, Trauner M, Fuhrmann V. Liver Injury and Failure in Critical Illness. Hepatology. 2019 Dec;70(6):2204-2215. PMID: 31215660.
  11. Cheung A, Flamm S. Hepatobiliary Complications in Critically Ill Patients. Clin Liver Dis. 2019 May;23(2):221-232. PMID: 30947873.
  12. Jenniskens M, Langouche L, Van den Berghe G. Cholestatic Alterations in the Critically Ill: Some New Light on an Old Problem. Chest. 2018 Mar;153(3):733-743. PMID: 28847548.
  13. Jenniskens M, Güiza F, Oorts M, Vander Perre S, Derde S, Dufour T, et al. On the Role of Illness Duration and Nutrient Restriction in Cholestatic Alterations that Occur During Critical Illness. Shock. 2018 Aug;50(2):187-198. PMID: 29076974. PMCID: PMC6039378.
  14. Leonhardt S, Veltzke-Schlieker W, Adler A, Schott E, Hetzer R, Schaffartzik W, et al. Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients. Crit Care. 2015;19:131. PMID: 25886728. PMCID: PMC4407292.
  15. Jenniskens M, Langouche L, Vanwijngaerden YM, Mesotten D, Van den Berghe G. Cholestatic liver (dys)function during sepsis and other critical illnesses. Intensive Care Med. 2016 Jan;42(1):16-27. PMID: 26392257.
  16. Tan KK, Bang SL, Vijayan A, Chiu MT. Hepatic enzymes have a role in the diagnosis of hepatic injury after blunt abdominal trauma. Injury. 2009 Sep;40(9):978-83. PMID: 19535055.
  17. Kozak DV. Dynamika pokaznykiv tsytolizu v umovakh politravmy [Dynamics of cytolysis in polytrauma]. Shpytalna khirurgiya. 2012;2:50-52. [Ukrainian]
  18. Kalynkyn OG, Lobanov GV, Grydasova EY, Kalynkyn AO, Alyev EF. Proyavlenye metabolycheskoy reaktsyy u postradavshykh s mnozhestvennoy y sochetannoy travmoy taza v ostrom y rannem peryodakh travmatycheskoy bolezny [Manifestation of a metabolic reaction in patients with multiple and concomitant pelvic trauma in the acute and early periods of traumatic illness]. Travmatologyya, ortopedyya y voennaya medytsyna. 2019;1:16-23. [Russian]
  19. Gudyma AA, Mykhaylyuk IA, Mykhaylyuk VM. Dynamika pokaznykiv zhovchoutvoryuvalnoyi funktsiyi pechinky u vidpovid na skeletnu, cherepno-mozkovu ta poyednanu travmy v ranniy period travmatychnoyi khvoroby [Dynamics of indicators of biliary function of the liver in response to skeletal, craniocerebral and combined injuries in the early period of traumatic illness]. Medychna ta klinichna khimiya. 2015;17(3):66-70. [Ukrainian].
  20. Blyznyuk RV, Uglyar YuV, Kozak DV. Vplyv khronichnogo gepatytu na dynamiku pokaznykiv tsytolizu i kholestazu v ranniy period pislya eksperymentalnoyi politravmy [Influence of chronic hepatitis on the dynamics of cytolysis and cholestasis in the early period after experimental polytrauma]. Aktualnye problemy transportnoy medytsyny. 2015;4(2):142-148. [Ukrainian]
  21. Prydruga SM, Bondarenko YuI, Borys RM. Dynamika pokaznykiv tsytolizu ta endogennoyi intoksykatsiyi v period piznikh proyaviv travmatychnoyi khvoroby ta yikh korektsiya tiotryazolinom [Dynamics of cytolysis and endogenous intoxication in the period of late manifestations of traumatic disease and their correction by thiotriazoline]. Klinichna ta eksperymentalna patologiya. 2013;12(1(43)):42-45. [Ukrainian].
  22. Kozak DV, Volkov KS. Elektronnomikroskopichnyy stan pechinky pry eksperymentalniy politravmi [Electron microscopic state of the liver in experimental polytrauma]. Svit medytsyny ta biologiyi. 2014;2(44):126-128. [Ukrainian]
  23. Mykhaylyuk IA, Gudyma AA, Mykhaylyuk VM. Dynamika pokaznykiv tsytolizu v umovakh rannogo periodu travmatychnoyi khvoroby pislya skeletnoyi, cherepno-mozkovoyi travmy ta yikh poyednannya [Dynamics of cytolysis in the early period of traumatic disease after skeletal, traumatic brain injury and their combination]. Visnyk naukovykh doslidzhen. 2015;1:120-122. [Ukrainian]
  24. Fox A, Sanderlin JB, McNamee S, Bajaj JS, Carne W, Cifu DX. Elevated liver enzymes following polytraumatic injury. J Rehabil Res Dev. 2014;51(6):869-74. PMID: 25479083.
  25. Sanfilippo F, Veenith T, Santonocito C, Vrettou CS, Matta BF. Liver function test abnormalities after traumatic brain injury: is hepato-biliary ultrasound a sensitive diagnostic tool? Br J Anaesth. 2014 Feb;112(2):298-303. PMID: 24067331.
  26. Nizamutdinov D, DeMorrow S, McMillin M, Kain J, Mukherjee S, Zeitouni S, et al. Hepatic alterations are accompanied by changes to bile acid transporter-expressing neurons in the hypothalamus after traumatic brain injury. Sci Rep. 2017 Jan 20;7:40112. PMID: 28106051. PMCID: PMC5247752.
  27. Fox A, Sanderlin JB, McNamee S, Bajaj JS, Carne W, Cifu DX. Elevated liver enzymes following polytraumatic injury. J Rehabil Res Dev. 2014;51(6):869-74. PMID: 25479083.
  28. Dudchenko MA. Klynycheskye osobennosty techenyya kalkuleznogo kholetsystyta s reaktyvnym gepatytom i metody ikh lechenyya [Clinical features of the course of calculous cholecystitis with reactive hepatitis and methods of their treatment]. Problemy ekologyy y medytsyny. 2013;17(1-2):65-66. [Russian]
  29. Thapa PB, Maharjan DK, Suwal B, Byanjankar B, Singh DR. Serum Gammaglutamyl transpeptidase and alkaline phosphatase in acute cholecystitis. J Nepal Health Res Counc. 2010;8(17):78-81.
  30. Rangaswamy R, Singh CG, Singh HM, Punyabati P, Nyuwi KT. Impact of Biliary Calculi on the Liver. J Clin Diagn Res. 2017 Apr;11(4):PC04-PC07. PMID: 28571204. PMCID: PMC5449850.
  31. Tkach SM. Zabolevanyya pecheny i pechenochnaya dysfunktsyya u bolnykh s serdechnoy nedostatochnostyu [Liver disease and hepatic dysfunction in patients with heart failure]. Sertseva nedostatnist ta komorbidni stany. 2017;3:90-96. [Russian]
  32. Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K, et al.; CHARM Investigators. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009 Feb;11(2):170-7. PMID: 19168515. PMCID: PMC2639422.
  33. van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail. 2010 Jan;16(1):84-90. PMID: 20123323.
  34. Poelzl G, Eberl C, Achrainer H, Doerler J, Pachinger O, Frick M, Ulmer H. Prevalence and prognostic significance of elevated gamma-glutamyltransferase in chronic heart failure. Circ Heart Fail. 2009 Jul;2(4):294-302. PMID: 19808352.
  35. Birrer R, Takuda Y, Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med. 2007;46(14):1063-70. PMID: 17634701.
  36. Saner FH, Heuer M, Meyer M, Canbay A, Sotiropoulos GC, Radtke A, et al. When the heart kills the liver: acute liver failure in congestive heart failure. Eur J Med Res. 2009;14(12):541-6. PMID: 20149988. PMCID: PMC3351940.
  37. Fuhrmann V, Jäger B, Zubkova A, Drolz A. Hypoxic hepatitis - epidemiology, pathophysiology and clinical management. Wien Klin Wochenschr. 2010 Mar;122(5-6):129-39. PMID: 20361374.
  38. Chen T, Li R, Chen P. Gut Microbiota and Chemical-Induced Acute Liver Injury. Front Physiol. 2021 May 26;12:688780. PMID: 34122150. PMCID: PMC8187901.
  39. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014 May;146(6):1513-24. PMID: 24440671. PMCID: PMC3996054.
  40. Yang X, Lu D, Zhuo J, Lin Z, Yang M, Xu X. The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases. Int J Biol Sci. 2020 Jun 23;16(13):2357-2366. PMID: 32760203. PMCID: PMC7378637.
  41. Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, et al. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int J Mol Sci. 2019 Jan 17;20(2):395. PMID: 30658519. PMCID: PMC6358912.
  42. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017 Jan;112(1):18-35. PMID: 27995906.
  43. Oh RC, Hustead TR, Ali SM, Pantsari MW. Mildly Elevated Liver Transaminase Levels: Causes and Evaluation. Am Fam Physician. 2017 Dec 1;96(11):709-715.
  44. Radcke S, Dillon JF, Murray AL. A systematic review of the prevalence of mildly abnormal liver function tests and associated health outcomes. Eur J Gastroenterol Hepatol. 2015;27:1-7. PMID: 25380394.
  45. Kolahdoozan S, Mirminachi B, Sepanlou SG, Malekzadeh R, Merat S, Poustchi H. Upper Normal Limits of Serum Alanine Aminotransferase in Healthy Population: A Systematic Review. Middle East J Dig Dis. 2020 Jul;12(3):194-205. PMID: 33062225. PMCID: PMC7548087.
  46. Liu Z, Que S, Xu J, Peng T. Alanine aminotransferase-old biomarker and new concept: a review. Int J Med Sci. 2014;11:925-35. PMID: 25013373. PMCID: PMC4081315.
  47. Vardar BU, Dupuis CS, Goldstein AJ, Vardar Z, Kim YH. Ultrasonographic evaluation of patients with abnormal liver function tests in the emergency department. Ultrasonography. 2022 Apr;41(2):243-262. PMID: 35026887. PMCID: PMC8942730.
  48. Sanfilippo F, Veenith T, Santonocito C, Vrettou CS, Matta BF. Liver function test abnormalities after traumatic brain injury: is hepato-biliary ultrasound a sensitive diagnostic tool? Br J Anaesth. 2014 Feb;112(2):298-303. PMID: 24067331.
  49. Donners R, Zaugg C, Gehweiler JE, Boldanova T, Heim MH, Terracciano LM, Boll DT. Computed tomography (CT) and magnetic resonance imaging (MRI) of diffuse liver disease: a multiparametric predictive modelling algorithm can aid categorization of liver parenchyma. Quant Imaging Med Surg. 2022 Feb;12(2):1186-1197. PMID: 35111615. PMCID: PMC8739153.